Literature DB >> 1277708

Absorption, metabolism, and excretion of hydrochlorothiazide.

B Beermann, M Groschinsky-Grind, A Rosén.   

Abstract

14C-hydrochlorothiazide (hct) was administered orally (n=4) and iv (n = 2 to healthy subjects. The gastrointestinal absorption ranged between 60% and 80%, most of it took place in the duodenum and the upper jejunum. The radioactivity was eliminated mainly in the urine, while no sigificant biliary excretion was observed. Chromatographic analysis of the urinary radioactivity demonstrated that greater than 95% of the absorbed or injected 14C-hct was excreted unchanged. The radioactivity in plasma during the first 10 hr after oral administration declined with a fast phase but the levels of label thereafter suggested a slow phase. The existence of such a phase was verified in 1 subject given 75 mg hct orally. His plasma levels of hct (determined with gas-liquid chromatography) declined according to a 2-compartment model, the half-lives of the alpha-and beta-phases being 1.7 and 13.1 hr, respectively. Hct accumulated in the blood cells and the ratio between the radioactivity in cells and that in plasma averaged 3.5. The fate of a single dose of 14C-hct in 2 hypertensive patients treated with the drug chronically was similar to that in the healthy subjects. A third patient, who had slightly elevated serum creatinine, eliminated hct more slowly than the others. Like the healthy subjects, the patients eliminated hct to greater than 95% in unchanged form.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277708     DOI: 10.1002/cpt1976195part1531

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  38 in total

1.  Permeability characteristics of various intestinal regions of rabbit, dog, and monkey.

Authors:  N Jezyk; W Rubas; G M Grass
Journal:  Pharm Res       Date:  1992-12       Impact factor: 4.200

2.  Column-switching high-performance liquid chromatographic (HPLC) determination of hydrochlorothiazide in rat, dog, and human plasma.

Authors:  B S Kuo; A Mandagere; D R Osborne; K K Hwang
Journal:  Pharm Res       Date:  1990-12       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

Review 4.  Pharmacologic treatment of chronic pediatric hypertension.

Authors:  Renee F Robinson; Milap C Nahata; Donald L Batisky; John D Mahan
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 5.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

6.  Bioavailability of two hydrochlorothiazide preparations.

Authors:  B Beermann; M Groschinsky-Grind; B Lindstrom
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

7.  Gastrointestinal absorption of hydrochlorothiazide enhanced by concomitant intake of food.

Authors:  B Beermann; M Groschinsky-Grind
Journal:  Eur J Clin Pharmacol       Date:  1978-05-17       Impact factor: 2.953

8.  Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach.

Authors:  Floriane Lignet; Eva Sherbetjian; Nicole Kratochwil; Russell Jones; Claudia Suenderhauf; Michael B Otteneder; Thomas Singer; Neil Parrott
Journal:  Pharm Res       Date:  2016-07-28       Impact factor: 4.200

9.  Pharmacokinetics of hydrochlorothiazide in relation to renal function.

Authors:  C Niemeyer; G Hasenfuss; U Wais; H Knauf; M Schäfer-Korting; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 10.  Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.